The largest U.S. banks are scrutinizing members of the Federal Reserve for any insight into how the central bank will tinker interest rates.Banksread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
The U.S. and China restarted their trade talks, but signs are showing a comprehensive deal could be a long way off, if it happens at all.Marketsread more
Stone, 66, a notorious Republican political operative who has described himself as a "dirty trickster," had previously been dressed down by the judge for his public remarks...Politicsread more
The Biden team's second-quarter Federal Election Commission filing shows that the campaign wrote a check of just over $5,300 on June 28 to Sheehan Associates for "strategic...2020 Electionsread more
See which stocks are posting big moves after the bell on July 16.Market Insiderread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
United Airlines' second-quarter profit tops estimates but questions about the 737 Max linger.Airlinesread more
Three civil rights groups filed a federal lawsuit on Tuesday challenging the Trump administration's new asylum rule, which bars asylum claims from most noncitizens who travel...Politicsread more
Google VP of policy Karan Bhatia started sweating early as hearing chair Ted Cruz brings out an internal presentation created within the company.Technologyread more
At a hearing with the House Judiciary subcommittee on antitrust, an Amazon representative disputed a key argument about how it users sellers' data.Technologyread more
Jim Cramer has found one speculative biopharmaceutical company that has already quadrupled and isn't done rewarding your portfolio, yet.
Receptos is a biopharmaceutical company that is focused on therapeutics for immune disorders. The stock took off in 2014, thanks to its clinical trial data for a drug called Ozanimod, which treats multiple sclerosis. Cramer sees enormous potential with this drug, which could even be worth billions.
Ozanimod is currently in Phase 3 trials as an oral treatment, and thus far, the data has indicated it is better than the competition oral treatment drug for MS.
Additionally, there are studies underway that have strong data indicating it could also treat ulcerative colitis and Crohn's disease, and in the long-term it could work for diseases like lupus or psoriasis, as well.
Could the healthy outlook translate into hefty investor profits? To find out, Cramer spoke with Receptos CEO Faheem Hasnain.
"Our efficacy data looks every bit as good, and, importantly, our safety profile seems to be a real improvement for patients with this disease," Hasnain said.
The CEO clarified that the significance of Ozanimod is that there is an unmet need for drugs to treat the disease once steroids or immune suppressants no longer work. Receptos' drug is a pill taken once daily, unlike the other options, which are given through IV or injections.
Additionally, a third of patients flare within a year of taking steroids and require more aggressive treatment. A third of patients don't even respond to biologics, and, of the ones that do, only 50 percent will have a durable response.
Hasnain thinks this speaks to the large need for patients who are living with the disease and really need new options.
"I think it is fair to say that this data is as good as it gets. Certainly as good as any of the biologics," he added.
The potential for Receptos could be huge, as there are three times as many patients living with inflammatory bowel disease than multiple sclerosis. So, if this new drug can treat ulcerative colitis, it will open the door to much wider use.
Read more from Mad Money with Jim Cramer
Cramer Remix: This one stock leading many higher
Cramer: Secret catalyst behind the housing boom
Cramer: The stock rotation ruining your portfolio
"We have been known up until this point in time as a multiple sclerosis company because of our first set of trials that we read out…What is really exciting and what's new is this data in inflammatory bowel disease, ulcerative colitis, specifically," Hasnain said.
Even Cramer thinks the pipeline holds plenty of potential for investors, saying, "This is real. This is a major drug that could have multiple indications. Receptos is a very, very exciting speculative stock."